Help your patients with PI reconnect

Patients with PI taking CUVITRU may be able to experience more of these moments with weekly or every-other-week infusions.1

CUVITRU® can be infused at the fastest rates or highest volumes with the fewest needlesticks of any SCIG, without sacrificing tolerability1,2

Clock icon.

How fast?

The median duration of once-weekly infusions was <1 hour (0.95 hours; range: 0.2-6.4 hours) in the North American clinical study.

  • CUVITRU may allow delivery of a full week’s dose in <15 minutes–with even shorter durations possible with more frequent dosing*
  • Approximately 94% of infusions were completed within 2 hours3
  • Infuse at rates up to 60 mL/h/site in up to 4 sites simultaneously for a maximum total of 240 mL/h. Infuse first 2 infusions at 10 to 20 mL/h/site

*If a patient is 75 kg (165 lb) and has been prescribed 36 g of IVIG per month, you could switch your patient to 12 g of CUVITRU weekly. After the first 2 infusions, subsequent infusions of CUVITRU could be completed in 15 minutes at a rate of 60 mL/h/site using 4 sites simultaneously.

Icon Injection Orange

What did this mean to patients?

  • Infuse at volumes up to 60 mL/site in up to 4 sites simultaneously for a maximum volume of 240 mL/h. Infuse first 2 infusions at 10 to 20 mL/h/site
  • With the highest infusion volume (60 mL/h/site, as tolerated) compared to any other conventional SCIG option, a daily, weekly, or every-other-week infusion schedule is possible for your patients 
  • Your patients can create a treatment plan that meets their schedule
&#34;1 - 2 sites&#34; inside of a circle.

How few?

84.9% (N=4314) of infusions were administered using only 1 or 2 infusion sites (18.5%=1 site; 66.4%=2 sites) in the North American clinical study.

  • Infuse weekly in <1 hour in 1-2 sites
  • The use of more infusion sites may be beneficial for patients who want to reduce the volume administered per site or overall infusion duration

Well-tolerated administration1: 98.2% (4247/4327) of infusions had no local ARs—and local tolerability remained the same, even at higher volumes and rates. 2 of 3 patients had no local ARs, such as pain, erythema, and pruritus. The most common ARs overall were local ARs and systemic ARs including headache, nausea, fatigue, diarrhea, and vomiting.

SCIG=subcutaneous immune globulin.

Flexible treatment schedules could mean more time for yoga

Getting started with CUVITRU

To see important information for starting your patients on CUVITRU, explore the tabs below.

Explore administration combinations

Use the infusion calculator to determine CUVITRU administration parameter combinations for your patients based on needlesticks and frequency of infusions, and help your patients achieve CUVITRU’s maximum infusion rate by selecting the proper supplies.

Infusion calculator

Choose from the following parameters to find the right dosing plan for you and your patient.

Calendar icon.

SCIG dose

Syringe and needle icon.


Clock icon.


Needlesticks 1 2 3 4
Milliliter drop icon.


per SCIG
20% infusion

The dosing calculator is meant to be used as a tool to help HCPs make informed decisions about dosing. Takeda is not making dosing recommendations.

CUVITRU: Maximum volume per site is 60 mL/site as tolerated (except for the first 2 infusions for patients <40 kg, for whom the maximum volume is 20 mL/site). Maximum infusion rate is 60mL/h/site as tolerated (after first 2 infusions). Up to 4 sites can be used simultaneously.1

What is the patient's weight?


What is the dose schedule?

Dose calculation of CUVITRU*

Monthly dose Dose per infusion
300 mg/kg  
400 mg/kg  
500 mg/kg  
600 mg/kg  

*Monthly dose of CUVITRU is equivalent to current monthly dose of SCIG.

Current monthly dose of IVIG/HyQvia

Monthly dose 300 mg/kg 400 mg/kg 500 mg/kg 600 mg/kg

Dose calculation of CUVITRU

Current monthly dose of IVIG/HyQvia Dose calculation of CUVITRU
Monthly dose Monthly dose Dose per infusion
300 mg/kg 390 mg/kg  
400 mg/kg 520 mg/kg  
500 mg/kg 650 mg/kg  
600 mg/kg 780 mg/kg  

For more information about HyQvia, please see Full Prescribing Information

Monthly dose of CUVITRU is calculated based on a dose adjustment factor of 1.30.

This calculator does not represent every possible weight calculation. Weights begin as 24 lb and increase in 4 lb increments to 288 lb.

See Full Prescribing Information for additional dosage recommendations. A conversion factor of 2.2046 lb/kg is used to convert the patient’s weight to kilograms. The values displayed are rounded to the nearest decimal point.

Select CUVITRU vial combinations based on dosage

CUVITRU is available in 1 g, 2 g, 4 g, 8 g, and 10 g vials of IG 20%. The dose must be rounded up or down, based on the physician’s clinical judgement.

IV bag icon.

View examples of 2 patients’ infusion sites from pre-infusion to 24 hours after.

Volume infused per physician guidance based on patient’s specific clinical condition. It may be different for other patients. Infuse first 2 infusions at 10 to 20 mL/h/site.

Patient No. 1: Male, age 59 

  • 60 mL infusion in 1 site of the abdomen
  • Infused at maximum rate of 60 mL/h/site
  • 60-minute infusion

Patient No. 2: Female, age 14

  • 40 mL infusion in 1 site of the thigh
  • Infused at rate of 40 mL/h/site
  • 60-minute infusion

The most common adverse reactions observed in clinical trials in ≥5% of patients were local adverse reactions including mild or moderate pain, erythemia, and pruritus.

Beginning patients on CUVITRU in a few steps 

Learn about starting patients on CUVITRU


  1. CUVITRU. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023.
  2. Suez D, Stein M, Gupta S, et al. Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America. J Clin Immunol. 2016;36(7):700-712.
  3. Data on file. Takeda US Inc. 2015.